Search results for "glycemia"

showing 10 items of 159 documents

Advanced Glycation End Products: New Clinical and Molecular Perspectives

2021

Diabetes mellitus (DM) is considered one of the most massive epidemics of the twenty-first century due to its high mortality rates caused mainly due to its complications; therefore, the early identification of such complications becomes a race against time to establish a prompt diagnosis. The research of complications of DM over the years has allowed the development of numerous alternatives for diagnosis. Among these emerge the quantification of advanced glycation end products (AGEs) given their increased levels due to chronic hyperglycemia, while also being related to the induction of different stress-associated cellular responses and proinflammatory mechanisms involved in the progression …

Glycation End Products Advancedmedicine.medical_specialtyHealth Toxicology and Mutagenesis030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyFluorescence03 medical and health sciences0302 clinical medicineChronic hyperglycemiaGlycationDiabetes mellitusskin fluorescencemedicineHumansIntensive care medicineSkinbusiness.industryadvanced glycation end productsHigh mortalityPublic Health Environmental and Occupational HealthRmedicine.diseasechronic complicationsHyperglycemiadiabetes mellitusMedicinebusinessInternational Journal of Environmental Research and Public Health
researchProduct

Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance

1992

Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the sodium-pump mechanism. We studied 14 hypertensive and 12 normotensive subjects with obesity and glucose intolerance for fasting blood glucose, and plasma insulin, C-peptide and EDLF levels: the two groups were matched for age and BMI and were studied after a 2-week wash-out period from hypotensive drugs. Compared with normotensives, hypertensive subjects had higher plasma insulin levels, a greater…

Blood GlucoseMaleDigoxinmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndogenyEndogenous digoxin-like factorEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicineHumansInsulinMedicineObesityImmunoreactive insulinC-Peptidebusiness.industryInsulinBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle AgedSaponinsmedicine.diseaseObesityCardenolidesEndocrinologyHyperglycemiaHypertensionFemaleInsulin ResistanceSodium-Potassium-Exchanging ATPasebusinessIntracellularActa Diabetologica
researchProduct

Impact of diet-induced obesity on the mouse brain phosphoproteome

2018

Obesity is closely associated to several diseases such as type 2 diabetes, cardiovascular disease, hepatic steatosis, airway disease, neurodegeneration, biliary diseases and certain cancers. It is, therefore, of importance to assess the role of nutrition in disease prevention as well as its effect in the course of such pathologies. In the present study, we addressed the impact of the exposure to different obesogenic diets in the mice brains phosphoproteome. To analyze if the obesity could be able to modify the protein pattern expression of brain neurons, obesity was induced in two different groups of mice. One group of mice was fed with hyperglycemic diet (HGD) and the other one was fed wit…

Male0301 basic medicinemedicine.medical_specialtyPhosphoproteomicsEndocrinology Diabetes and MetabolismClinical BiochemistryHyperglycemic dietType 2 diabetesDiseaseBiologyDiet High-FatBiochemistry03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsProtein phosphorylationObesityPhosphorylationMolecular BiologyGSK3BNutritionNeuronal impairmentNutrition and DieteticsNeurodegenerationta1182BrainObesity; Nutrition; High-fat diet; Hyperglycemic diet; Neuronal impairment; PhosphoproteomicsPhosphoproteinsmedicine.diseaseObesityMice Inbred C57BLHigh-fat dietGene Ontology030104 developmental biologyEndocrinologyHyperglycemiaPhosphorylationCalcium ChannelsSteatosis030217 neurology & neurosurgeryThe Journal of Nutritional Biochemistry
researchProduct

Pterostilbene Prevents Early Diabetic Retinopathy Alterations in a Rabbit Experimental Model

2019

Oxidative stress generated by diabetes plays a key role in the development of diabetic retinopathy (DR), a common diabetic complication. DR remains asymptomatic until it reaches advanced stages, which complicate its treatment. Although it is known that good metabolic control is essential for preventing DR, knowledge of the disease is incomplete and an effective treatment with no side effects is lacking. Pterostilbene (Pter), a natural stilbene with good antioxidant activity, has proved to beneficially affect different pathologies, including diabetes. Therefore, our study aimed to analyse the protective and/or therapeutic capacity of Pter against oxidant damage by characterising early retina…

Male0301 basic medicinepterostilbenePterostilbeneretinal damageNF-E2-Related Factor 2lcsh:TX341-641Pharmacologymedicine.disease_causeAntioxidantsArticlePhosphatidylinositol 3-Kinases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusStilbenesmedicineAnimalsoxidative stressProtein kinase BPI3K/AKT/mTOR pathwayType 1 diabetesGlycogen Synthase Kinase 3 betaNutrition and Dieteticsbusiness.industryDiabetic retinopathymedicine.diseaseEnzyme ActivationDisease Models Animaldiabetic retinopathypolyphenol030104 developmental biologychemistryHyperglycemia030220 oncology & carcinogenesisMetabolic control analysisRabbitsbusinesslcsh:Nutrition. Foods and food supplyProto-Oncogene Proteins c-aktOxidative stressSignal TransductionFood ScienceNutrients
researchProduct

PIK3R1 Mutations Cause Syndromic Insulin Resistance with Lipoatrophy

2013

International audience; Short stature, hyperextensibility of joints and/or inguinal hernia, ocular depression, Rieger anomaly, and teething delay (SHORT) syndrome is a developmental disorder with an unknown genetic cause and hallmarks that include insulin resistance and lack of subcutaneous fat. We ascertained two unrelated individuals with SHORT syndrome, hypothesized that the observed phenotype was most likely due to de novo mutations in the same gene, and performed whole-exome sequencing in the two probands and their unaffected parents. We then confirmed our initial observations in four other subjects with SHORT syndrome from three families, as well as 14 unrelated subjects presenting wi…

ProbandEXPRESSIONmedicine.medical_specialty030209 endocrinology & metabolismBiologymedicine.disease_causeMICE LACKINGShort stature03 medical and health sciencesHYPOGLYCEMIA0302 clinical medicineInsulin resistancePIK3R1Internal medicineReportmedicineGeneticsKINASEGenetics(clinical)LipoatrophyGenetics (clinical)030304 developmental biology0303 health sciencesMutationAKT2[SDV.GEN]Life Sciences [q-bio]/GeneticsRECEPTORmedicine.disease3-KINASE3. Good healthInsulin receptorEndocrinologyAUTOPHOSPHORYLATIONSHORT syndromebiology.proteinSKELETAL-MUSCLEGROWTHmedicine.symptom[ SDV.GEN ] Life Sciences [q-bio]/Genetics
researchProduct

Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia …

2020

The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles' heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Societa Italiana Farmacologia (SIF)…

diabetes; dyslipidemia; hypercholesterolemia; hyperglycemia; hypertriglyceridemia; immunotherapy; metabolic effect; targeted therapy; Consensus; Humans; Immunologic Factors; Italy; Medical Oncology; Neoplasms; Physicians0301 basic medicinemedicine.medical_specialtyConsensusSettore MED/06 - Oncologia MedicaImmune checkpoint inhibitorsmedicine.medical_treatmentPatient riskhypertriglyceridemiaMedical OncologyTargeted therapy03 medical and health sciences0302 clinical medicineMultidisciplinary approachNeoplasmsPhysiciansmedicineHumansImmunologic FactorsIntensive care medicineAdverse effectdiabeteshypercholesterolemiabusiness.industrydyslipidemiametabolic effectHematologytargeted therapy030104 developmental biologyOncologyItalyClinical evidence030220 oncology & carcinogenesisMetabolic effectsPosition paperhyperglycemiaimmunotherapybusiness
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

A single acute dose of pinitol from a naturally-occurring food ingredient decreases hyperglycaemia and circulating insulin levels in healthy subjects.

2013

A limited amount of research suggests that oral ingestion of pinitol (3-O-methyl-d-chiro-inositol) positively influences glucose tolerance in humans. This study assessed the effects of different doses of pinitol supplementation on glucose tolerance, insulin sensitivity and plasma pinitol concentrations. Thirty healthy subjects underwent two one-day trials in which they consumed a nutritive beverage (Fruit Up®) containing 2.5, 4.0 or 6.0g of pinitol and a corresponding placebo equivalent in both energy and carbohydrates. Blood samples were collected frequently over the 240-min test period. The pinitol-enriched beverage reduced serum glucose and insulin at 45 and 60min, but only at a dose of …

AdultBlood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentBlood sugarDown-RegulationPlaceboAnalytical ChemistryBeverageschemistry.chemical_compoundIngredientBlood serumInternal medicinemedicineIngestionHumansInsulinPinitolbusiness.industryInsulinGeneral MedicineEndocrinologychemistryBlood chemistryHyperglycemiaFemalebusinessInositolFood Science
researchProduct

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

2010

The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabe…

cardiovascular riskGlucose-lowering therapyEndocrinology Diabetes and MetabolismeducationSocieties Medical/standardsMEDLINE10265 Clinic for Endocrinology and DiabetologyHypoglycemic Agents/therapeutic use610 Medicine & healthType 2 diabetesHyperglycemia/drug therapyLifestyle modificationRisk FactorsDiabetes mellitusTier 2 networkADA Consensus StatementmedicineInternal MedicineInitial treatmentHyperglycaemiaHumansIn patientFor Debatealgorithmbusiness.industrynutritional and metabolic diseasesType 2 diabetesmedicine.diseaseCardiovascular riskUnited StatesMetforminEASD consensus statementglucose-lowering therapyAlgorithmEurope2712 Endocrinology Diabetes and Metabolism2724 Internal Medicine*AlgorithmsDiabetes Mellitus Type 2/complications/*drug therapytype 2 diabetesbusinessAlgorithmCardiovascular Diseases/prevention & controlhyperglycaemiamedicine.drug
researchProduct

GLP-1 Receptor agonists and diabetic kidney disease: A call of attention to nephrologists

2020

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 r…

medicine.medical_specialtyMedicinaRenal functionlcsh:Medicine030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyHypoglycemiaurologic and male genital diseases03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineChronic kidney diseaseMedicineMalalties cròniquesDiabetic kidney diseaseGlycemicKidneyProteinuriaKidney diseasesbusiness.industrylcsh:RType 2 Diabetes MellitusGeneral Medicinemedicine.diseasediabetic kidney diseasemedicine.anatomical_structureChronic diseasesMalalties del ronyómedicine.symptombusinessGLP-1chronic kidney diseaseKidney disease
researchProduct